{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:07:27Z","timestamp":1793052447646,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.biopha.2022.112746","type":"journal-article","created":{"date-parts":[[2022,2,25]],"date-time":"2022-02-25T23:47:28Z","timestamp":1645832848000},"page":"112746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["\u201cAducanumab\u201d making a comeback in Alzheimer\u2019s disease: An old wine in a new bottle"],"prefix":"10.1016","volume":"148","author":[{"given":"Tapan","family":"Behl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishnoor","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz A.","family":"Makeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Albratty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan A.","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shatha Ghazi","family":"Felemban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal M.","family":"Alsubayiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.112746_bib1","unstructured":"World Health Organization, Dementia, 2020, \u3008https:\/\/www.who.int\/news-room\/fact942sheets\/detail\/dementia\u3009."},{"key":"10.1016\/j.biopha.2022.112746_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer\u2019s disease facts and figures","volume":"16","author":"Alzheimer\u2019s Association","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopha.2022.112746_bib3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.112746_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","article-title":"Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990-2016: a systematic analysis 981 for the Global Burden of Disease Study 2016","volume":"18","author":"Nichols","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2022.112746_bib5","first-page":"208","article-title":"Drugs for 984 Alzheimer\u2019s disease: are they effective?","volume":"35","author":"Casey","year":"2010","journal-title":"PT"},{"key":"10.1016\/j.biopha.2022.112746_bib6","unstructured":"FDA, FDA Grants Accelerated Approval 986 for Alzheimer\u2019s Drug, (2021) \u3008https:\/\/www.fda.gov\/news-987events\/press-announcements\/fda-grants-accelerated-988approval-alzheimers-drug\u3009."},{"key":"10.1016\/j.biopha.2022.112746_bib7","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3233\/JAD-215065","article-title":"A primer on the evolution of Aducanumab: The first antibody approved for treatment of Alzheimer\u2019s disease","volume":"83","author":"Mukhopadhyay","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2022.112746_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.npep.2015.06.008","article-title":"Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer\u2019s disease","volume":"52","author":"Barage","year":"2015","journal-title":"Neuropeptides"},{"key":"10.1016\/j.biopha.2022.112746_bib9","first-page":"89","article-title":"Alzheimer\u2019s disease: a brief review","volume":"1","author":"McGirr","year":"2020","journal-title":"J. Exp. Neurol."},{"key":"10.1016\/j.biopha.2022.112746_bib10","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.2147\/IJN.S200490","article-title":"Alzheimer\u2019s disease: pathogenesis","volume":"14","author":"Tiwari","year":"2019","journal-title":"Diagn. Ther. Int. J. Nanomed."},{"issue":"8","key":"10.1016\/j.biopha.2022.112746_bib11","article-title":"Aducanumab as a novel treatment for Alzheimer\u2019s disease: a decade of hope, controversies, and the future","volume":"13","author":"Esang","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2022.112746_bib12","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s12640-013-9398-z","article-title":"Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease","volume":"24","author":"Parsons","year":"2013","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.biopha.2022.112746_bib13","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1523\/JNEUROSCI.0420-17.2017","article-title":"Aducanumab therapy ameliorates calcium overload in a Mouse Model of Alzheimer\u2019s DIsease","volume":"37","author":"Gamage","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112746_bib14","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.biopha.2022.112746_bib15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2217\/imt.10.80","article-title":"Bapineuzumab: anti-\u03b2-amyloid monoclonal antibodies for the treatment of Alzheimer's disease","volume":"2","author":"Panza","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.biopha.2022.112746_bib16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112746_bib17","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.112746_bib18","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.neuron.2014.12.064","article-title":"Immunotherapeutic approaches for Alzheimer's disease","volume":"85","author":"Wisniewski","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2022.112746_bib19","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.neuron.2021.09.007","article-title":"Aducanumab and the \u201cpost-amyloid\u201d era of Alzheimer research?","volume":"109","author":"Musiek","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2022.112746_bib20","doi-asserted-by":"crossref","first-page":"20579","DOI":"10.1016\/S0021-9258(18)54746-3","article-title":"Molecular genetics of Alzheimer disease amyloid","volume":"266","author":"Tanzi","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2022.112746_bib21","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","article-title":"Neuropathology of older persons without cognitive impairment from two community-based studies","volume":"66","author":"Bennett","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2022.112746_bib22","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archneurol.2009.269","article-title":"Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease","volume":"66","author":"Morris","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.biopha.2022.112746_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40266-016-0406-x","article-title":"Antibody-based drugs and approaches against amyloid-\u03b2 species for Alzheimer\u2019s disease immunotherapy","volume":"33","author":"Liu","year":"2016","journal-title":"Drugs Aging"},{"key":"10.1016\/j.biopha.2022.112746_bib24","series-title":"Developing Therapeutics for Alzheimer\u2019s Disease","first-page":"193","article-title":"Anti-Amyloid-\u03b2 immunotherapy for Alzheimer\u2019s disease","author":"Crehan","year":"2016"},{"key":"10.1016\/j.biopha.2022.112746_bib25","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-\u03b2","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2022.112746_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.biopha.2022.112746_bib27","article-title":"Differential in vitro and in vivo binding profiles of BIIB037 and other anti-abeta clinical antibody candidates","volume":"11","author":"Bussiere","year":"2013","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.biopha.2022.112746_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting A\u03b2 and tau in Alzheimer\u2019s disease","volume":"144","author":"Plotkin","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.biopha.2022.112746_bib29","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.neuron.2008.06.008","article-title":"A\u03b2 plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks","volume":"59","author":"Kuchibhotla","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2022.112746_bib30","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1523\/JNEUROSCI.0617-19.2019","article-title":"Amyloid-beta modulates lowthreshold activated voltage-gated L-type calcium channels of arcuate neuropeptide Y neurons leading to calcium dysregulation and hypothalamic dysfunction","volume":"39","author":"Ishii","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112746_bib31","doi-asserted-by":"crossref","DOI":"10.14336\/AD.2021.0719","article-title":"Comparative analysis of Aducanumab, Zagotenemab and Pioglitazone as targeted treatment strategies for Alzheimer\u2019s disease","author":"Abyadeh","year":"2021","journal-title":"Aging Dis."},{"key":"10.1016\/j.biopha.2022.112746_bib32","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque specific antibody clears existing \u03b2-amyloid plaques in Alzheimer's disease mice","volume":"76","author":"DeMattos","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.biopha.2022.112746_bib33","doi-asserted-by":"crossref","first-page":"12549","DOI":"10.1523\/JNEUROSCI.2080-16.2016","article-title":"Immunotherapy with aducanumab restores calcium homeostasis in Tg2576 mice","volume":"36","author":"Kastanenka","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.biopha.2022.112746_bib34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/JAD-200715","article-title":"Anti-A\u03b2 antibody Aducanumab regulates the proteome of senile plaques and closely surrounding tissue in a transgenic Mouse Model of Alzheimer\u2019s disease","volume":"79","author":"Bastrup","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2022.112746_bib35","first-page":"169","article-title":"First-inhuman, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-tomoderate Alzheimer's disease","volume":"2","author":"Ferrero","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopha.2022.112746_bib36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2022.112746_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1474-4422(19)30480-6","article-title":"A resurrection of aducanumab for Alzheimer\u2019s disease","volume":"19","author":"Schneider","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2022.112746_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14728214.2020.1808621","article-title":"Anti-amyloid-\u03b2 protein agents for the treatment of Alzheimer\u2019s disease: an update on emerging drugs","volume":"25","author":"Lozupone","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.biopha.2022.112746_bib39","unstructured":"\u3008https:\/\/investors.biogen.com\u3009."},{"key":"10.1016\/j.biopha.2022.112746_bib40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40120-021-00273-0","article-title":"Predicted lifetime health outcomes for Aducanumab in patients with early Alzheimer\u2019s disease","author":"Herring","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.biopha.2022.112746_bib41","unstructured":"I.S. Padda, M. Parmar, 2021. Aducanumab."},{"key":"10.1016\/j.biopha.2022.112746_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab produced a clinically meaningful benefit in association with amyloid lowering","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.biopha.2022.112746_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1474-9726.2007.00275.x","article-title":"Calcium and neurodegeneration","volume":"3","author":"Mattson","year":"2007","journal-title":"Aging Cell"},{"key":"10.1016\/j.biopha.2022.112746_bib44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1113\/jphysiol.2013.257527","article-title":"Calcium regulation of neural rhythms, memory and Alzheimer's disease","volume":"592","author":"Berridge","year":"2014","journal-title":"J. Physiol."},{"key":"10.1016\/j.biopha.2022.112746_bib45","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/nn1503","article-title":"Regulation of NMDA receptor trafficking by amyloid-\u03b2","volume":"8","author":"Snyder","year":"2005","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.biopha.2022.112746_bib46","unstructured":"Drugs@FDA: FDA-Approved Drugs n.d. \u3008https:\/\/www.accessdata\u3009. fda.gov\/scripts\/cder\/daf\/(accessed June 14, 2021)."},{"key":"10.1016\/j.biopha.2022.112746_bib47","first-page":"496","article-title":"FDA approval for Biogen\u2019s aducanumab sparks Alzheimer disease firestorm","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.biopha.2022.112746_bib48","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2021.08.012","article-title":"How the US Food and Drug Administration\u2019s approval of aducanumab for Alzheimer\u2019s disease has implication for oncology and beyond","volume":"157","author":"Lythgoe","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2022.112746_bib49","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.mayocp.2016.02.012","article-title":"Strength of validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs","volume":"91","author":"Kim","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biopha.2022.112746_bib50","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.mayocp.2019.12.002","article-title":"Oncology Drug Advisory Committee recommendations and the US Food and Drug Administration\u2019s actions","volume":"95","author":"Haslam","year":"2020","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biopha.2022.112746_bib51","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2021.3046","article-title":"The oncologic drugs advisory committee votes of April 2021-implications for the fate of accelerated approval","volume":"7","author":"Powell","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.biopha.2022.112746_bib52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamainternmed.2020.5921","article-title":"Potential cost implications for All US Food and drug administration oncology drug approvals in 2018","volume":"181","author":"DeMartino","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.biopha.2022.112746_bib53","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/pnp.711","article-title":"Aducanumab and disease modifying treatments for Alzheimer\u2019s disease","volume":"25","author":"Thomas","year":"2021","journal-title":"Prog. Neurol. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112746_bib54","unstructured":"P. Belluck, R. Robbins, Three FDA Advisers Resign Over Agency's Approval of Alzheimer's Drug. www.nytimes.com\/2021\/06\/10\/health\/aduhelm-fda-resign-alzheimers.html; accessed 21 July 2021)."},{"key":"10.1016\/j.biopha.2022.112746_bib55","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-Amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.biopha.2022.112746_bib56","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jalz.2019.06.070","article-title":"Variability of ARIA detection in patients receiving monoclonal antibodies against amyloid beta plaques","volume":"15","author":"Gutt","year":"2019","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopha.2022.112746_bib57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.biopha.2022.112746_bib58","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/alz.12286","article-title":"ENGAGE and EMERGE: truth and consequences?","volume":"17","author":"Kuller","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.biopha.2022.112746_bib59","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3233\/JAD-210736","article-title":"The FDA approves Aducanumab for Alzheimer\u2019s disease, raising important scientific questions","volume":"82","author":"de la Torre","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.biopha.2022.112746_bib60","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2022.112746_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100988","article-title":"High cerebrospinal amyloid-\u03b2 42 is associated with normal cognition in individuals with brain amyloidosis","volume":"38","author":"Sturchio","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.biopha.2022.112746_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105754","article-title":"Aducanumab for Alzheimer\u2019s disease: a regulatory perspective","volume":"171","author":"Nistic\u00f2","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2022.112746_bib63","unstructured":"Alzheimer\u2019s Disease International, 2021. ADI-FDA approves Biogen\u2019s Aducanumab. \u3008https:\/\/www.alzint.org\/news\/fda-approves-biogens-aducanumab\/\u3009."},{"key":"10.1016\/j.biopha.2022.112746_bib64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0197-4580(00)00211-6","article-title":"Copernicus revisited: amyloid beta in Alzheimer\u2019s disease","volume":"22","author":"Josepha","year":"2001","journal-title":"Neurobiol. Aging"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222001342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222001342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:29:23Z","timestamp":1781764163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222001342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":64,"alternative-id":["S0753332222001342"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112746","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cAducanumab\u201d making a comeback in Alzheimer\u2019s disease: An old wine in a new bottle","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.112746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"112746"}}